

Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics

SUNNYVALE, Calif., March 18 /PRNewswire/ -- Arbor Vita Corporation (AVC), a privately held biotechnology company, today announced that Linda McAllister, M.D., Ph.D., has joined the company's management team as Vice President of Diagnostics, a new position. Dr. McAllister has recent experience in the life sciences and diagnostics industry as well as in clinical medicine and academic research, where her research focus included molecular genetics and DNA microarray applications in human genetics.

"We are delighted about Linda's decision to join Arbor Vita at this time," commented Peter S. Lu, M.D., Founder, President and Chief Executive Officer. "Linda brings to AVC an impressive record of accomplishments that will be invaluable as she leads our diagnostic efforts. We believe that her grasp of new technologies combined with an understanding of the clinical practices and the competitive market will position AVC to great advantage for our diagnostics business going forward."

Most recently, Dr. McAllister was Director of Technology Management at Roche Diagnostics, where she managed a portfolio of early-stage technology opportunities. Previously, she was Director of Clinical Genetics at Celera Diagnostics, where she negotiated access to and managed most of the clinical study samples. Prior to Celera, Dr. McAllister was Program Manager of Genotyping at Affymetrix, where she launched two products and is the inventor on a number of key patents. In addition to her business career, she simultaneously served as Adjunct Clinical Professor in the Department of Medicine at UCSF from 1992 to 2005. She received her B.S. in Biology and Chemistry from the California Institute of Technology and both a Ph.D. in Neurosciences and an M.D. from Stanford University Medical School. Dr. McAllister completed her residency in Internal Medicine at UCSF and was a Bugher Cardiovascular Research Fellow at Stanford under the direction of Drs. Victor Dzau, Patrick O. Brown and David Botstein. She is the author of numerous scientific publications and holds six patents.

"I am excited to be part of the Arbor Vita management team, and to help translate the company's elegant and powerful PDZ biology from research to the clinic," stated Linda McAllister, M.D., Ph.D. "The company is well poised to realize commercial success in the emerging field of personalized medicine, by leveraging its PDZ-enabling technology for both diagnostics and therapeutics. At Arbor Vita, I expect to continue my personal mission to improve healthcare through the delivery of novel technologies that have a positive impact on global health."

About Arbor Vita Corporation

Arbor Vita (<http://www.arborvita.com>) is a biotechnology company focused on the discovery, development, and commercialization of novel drugs and diagnostics addressing disease through a new family of targets, PDZ proteins. PDZ proteins are critical elements that organize and regulate many signaling pathways in human cells. Arbor Vita is pioneering the development of both therapeutics and diagnostics through their unique understanding of the role of PDZs in cell signaling and disease. The company is addressing major health issues including cervical cancer, stroke and cardiovascular disease as well as infectious diseases such as influenza.

CONTACT: Debra Bannister of Arbor Vita Corporation, +1-530-676-8001

Web site: <http://www.arborvita.com/>